163 related articles for article (PubMed ID: 12431495)
1. Efficacy and safety of atorvastatin after pediatric heart transplantation.
Chin C; Gamberg P; Miller J; Luikart H; Bernstein D
J Heart Lung Transplant; 2002 Nov; 21(11):1213-7. PubMed ID: 12431495
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
[TBL] [Abstract][Full Text] [Related]
4. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of atorvastatin in heart transplant recipients.
Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Maltz HC; Balog DL; Cheigh JS
Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.
Argent E; Kainer G; Aitken M; Rosenberg AR; Mackie FE
Pediatr Transplant; 2003 Feb; 7(1):38-42. PubMed ID: 12581326
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
10. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
März W; Wollschläger H; Klein G; Neiss A; Wehling M
Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
[TBL] [Abstract][Full Text] [Related]
11. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Ikejiri A; Hirano T; Murayama S; Yoshino G; Gushiken N; Hyodo T; Taira T; Adachi M
Metabolism; 2004 Sep; 53(9):1113-7. PubMed ID: 15334369
[TBL] [Abstract][Full Text] [Related]
14. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
17. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B
Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
